No, I have followed Jason pretty closely over the
Post# of 30028
I hope this doesn't make me seem irrational? The questions is, is it rational to believe we may not need a RS to up list? Is it rational to think we'll get a MANF partnership by year end? I think my taking a more realistic approach, following the lack of pps movement over the LymPro catalysts recently....is quite rational.
I think we'll move up nicely in 2015, but the first 6 to 9 months before LymPro revenue ramps up might be a bit weak. That is where my concern about dilution enters. Is that irrational to raise this concern? I think not.